B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks that nosedived in January, going from $42.98 to $32.75 on ...